Photo taken from: Arndt Vogel/Twitter
Oct 9, 2023, 00:35
Arndt Vogel: Off the press: Tislelizumab vs Sorafenib as 1st line Treatment for HCC JAMA Oncology.
Arndt Vogel, made the following post on Twitter:
“Off the press: Tislelizumab vs Sorafenib as 1st line Treatment for HCC JAMA Oncology.
- ORR: 14.3% vs 5.4%
- mOS: 15.9 vs 14.1mo
- non-inferiority, in line with Nivo & Durva, but we need a “niche” or a biomarker…”
For details click here.
Source: Arndt Vogel/Twitter
Arndt Vogel is a managing senior consultant and professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School. He is the Head of the GI-Cancer Center and of the Center for Personalized Medicine at Medical School Hannover and chairs the Hepatobiliary Cancer Study Group of the AIO, a collaborative group in clinical oncology in Germany. His scientific focus is translational and clinical research in gastrointestinal cancer.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14
Nov 14, 2024, 16:29
Nov 14, 2024, 16:27